Ignite Creation Date:
2025-12-24 @ 11:40 PM
Ignite Modification Date:
2025-12-25 @ 9:31 PM
Study NCT ID:
NCT06142851
Status:
UNKNOWN
Last Update Posted:
2023-11-22
First Post:
2023-11-15
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Management of Women With Superficial Dyspareunia
Sponsor:
Université de Reims Champagne-Ardenne
Organization:
Study Overview
Official Title:
Management of Women With Superficial Dyspareunia
Status:
UNKNOWN
Status Verified Date:
2023-11
Last Known Status:
NOT_YET_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
dyspareunie
Brief Summary:
Superficial dyspareunia are persistent or recurrent pains during an attempt at sexual intercourse or during effective penetration.
They affect between 3 to 18% of women and are a source of physical and psychological suffering.
Some health professionals (gynecologists, general practitioners, midwives) are confronted daily with these complaints.
The approach of sexuality remains a complex subject even within the medical field. As a result, communication between women and health professionals can be difficult, leading to delayed diagnosis or inadequate management.
They affect between 3 to 18% of women and are a source of physical and psychological suffering.
Some health professionals (gynecologists, general practitioners, midwives) are confronted daily with these complaints.
The approach of sexuality remains a complex subject even within the medical field. As a result, communication between women and health professionals can be difficult, leading to delayed diagnosis or inadequate management.
Detailed Description:
The main objective is to describe the management of superficial dyspareunia by health professionals.
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: